Martin Nilsson

Dr. Martin Nilsson

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2019 in Microorganisms
Verified
Journal Article
Open access
PDF file
MNMartin Nilsson
Martin Nilsson
MGMichael Givskov
Michael Givskov
STSvante Twetman
Svante Twetman
Tim Tolker-NielsenTim Tolker-Nielsen
Tim Tolker-Nielsen
Screening of a Streptococcus mutans mutant library indicated that pgmA mutants displayed a reduced biofilm-associated tolerance toward gentamicin. The biofilms formed by the S. mutans pgmA mutant also displayed decreased tolerance towards linezolid and vancomycin compared to wild-type biofilms. On the contrary, the resistance of planktonic S. mutans pgmA cells to gentamycin, linezolid, and vancomycin was more similar to wild-type levels. Investigations of biofilms grown in microtiter trays and on submerged glass slides showed that pgmA mutants formed roughly the same amount of biofilm as the wild type, indicating that the reduced antimicrobial tolerance of these mutants is not due to diminished biofilm formation. The pgmA gene product is known to be involved in the synthesis of precursors for cell wall components such as teichoic acids and membrane glycolipids. Accordingly, the S. mutans pgmA mutant showed increased sensitivity to Congo Red, indicating that it has impaired cell wall integrity. A changed cell wall composition of the S. mutans pgmA mutant may play a role in the increased sensitivity of S. mutans pgmA biofilms toward antibiotics.

Verified
Journal Article
Open access
PDF file
CJCharlotte Uldahl Jansen
Charlotte Uldahl Jansen
KGKatja Egeskov Grier
Katja Egeskov Grier
JAJens Bo Andersen
Jens Bo Andersen
LHLouise Dahl Hultqvist
Louise Dahl Hultqvist
MNMartin Nilsson
Martin Nilsson
KQKatrine Qvortrup
Katrine Qvortrup
This paper presents the work performed to transition a lab-scale synthesis (1 g) to a large-scale (400 g) synthesis of the 3-5-diamino-1H-Pyrazole Disperazol, a new pharmaceutical for treatment of antibiotic-resistant Pseudomonas aeruginosa biofilm infections. The potentially hazardous diazotisation step in the lab-scale synthesis was transformed to a safe and easy-to-handle flow chemistry step. Additionally, the paper presents an OSHA-recommended safety assessment of active compound E, as performed by Fauske and Associates, LLC, Burr Ridge, IL, USA.

27 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
CJCharlotte Uldahl Jansen
Charlotte Uldahl Jansen
KGKatja Egeskov Grier
Katja Egeskov Grier
JAJens Bo Andersen
Jens Bo Andersen
LHLouise Dahl Hultqvist
Louise Dahl Hultqvist
MNMartin Nilsson
Martin Nilsson
KQKatrine Qvortrup
Katrine Qvortrup
This paper presents the work done to transition the lab scale synthesis (1 g) to a large scale (400 g) synthesis of the 3-5-diamino-1H-Pyrazole Disperazol; a new pharmaceutical for treatment of antibiotic resistant Pseudomonas aeruginosa biofilm infections. The potentially hazardous diazotisation step in the lab scale synthesis was transformed to a safe and easy to handle flow chemistry step. Additionally, the paper presents an OSHA recommended safety assessment of the active compound E, performed by Fauske and Associates, LLC.